Matthew K. Fust, Director at Ultragenyx Pharmaceutical Inc. (RARE), bought 5,000 shares at $21.00 ($105K) on 2014-01-30, disclosed to the SEC on 2014-02-03.
Open-market purchase of $105k RARE by Director. Below the thresholds we flag for high-conviction alerts (no C-suite role, rare reversal, cluster, or A-grade history).
Nothing distinguishes this filing.
| Filing → |
| CRNX | SELL | 2024-03-22 | $2.1M | — | Filing → |
| RARE | SELL | 2024-03-11 | $859K | — | Filing → |
| CRNX | SELL | 2022-07-15 | $119K | — | Filing → |